title: "Assort Health Reaches $1.2B Valuation on $120M Series C" slug: "assort-health-reaches-12b-valuation-on-120m-series-c" published: "2026-07-15" beat: "Business" tags: ["Business"] creator: "Agentry Newsroom" editor: "Susanne Sperling, Editor — Human in the Loop" tools: ["Claude (Anthropic)", "Perplexity Sonar"] creativeWorkStatus: "verified" dateReviewed: "2026-07-15" aiActArticle50: "compliant" humanView: "https://agentry.news/assort-health-reaches-12b-valuation-on-120m-series-c" agentView: "https://agentry.news/agent/assort-health-reaches-12b-valuation-on-120m-series-c"
Assort Health, a San Francisco healthcare AI startup, closed a $120 million Series C funding round led by Menlo Ventures on June 25, 2026, achieving unicorn status at a $1.2 billion valuation. The com
Drafted by an AI agent. Verified by Susanne Sperling, Editor — Human in the Loop. AI policy.
Assort Health closed a $120 million Series C funding round, reaching unicorn status at a $1.2 billion valuation, according to PR Newswire on June 25, 2026. The San Francisco-based healthcare AI startup has now raised more than $222 million across all funding rounds.
Assort Health's AI agents automate core healthcare operations: patient scheduling, intake forms, referral routing, lab requests, medication refills, insurance eligibility verification, and payment processing. The company reports that its agents have handled 190 million patient interactions, demonstrating concrete operational scale rather than pilot-stage deployment. This volume positions Assort as the largest deployed agent system in healthcare patient workflow management.
The funding round was led by Menlo Ventures, with JP Sanday joining the company's board and Matt Murphy serving as board observer. Prior investors—Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, and Tau Ventures—participated in the round, alongside investor Joe Montana and Quiet Capital.
The timing reflects healthcare's documented administrative burden. Patient scheduling, eligibility checks, and referral coordination consume significant clinical and administrative labor. Assort's approach automates these workflows without replacing clinical staff, instead reducing the friction points that delay care and increase operational costs.
The Series C comes as enterprise adoption of AI agents for business process automation accelerates across sectors. Unlike earlier "agent" announcements focused on research or prototype capabilities, Assort's story is grounded in measurable deployment—190 million interactions is a concrete operational metric, not a planned feature or theoretical capability.
This funding round signals investor confidence in the agent economy as a business category. Assort's valuation climb—from seed through Series C—reflects the shift from general-purpose AI models to vertical, agent-based automation platforms that operate autonomous systems in specific domains. Healthcare's regulatory framework and high operational costs create both barriers to entry and strong unit economics once deployment reaches scale.
The company now has capital to expand its agent deployment, add more healthcare workflows, and scale its infrastructure to handle increasing interaction volumes. With $120 million in this round alone, Assort joins a cohort of agent-first companies proving that autonomous systems can drive measurable business outcomes in regulated industries.